Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?

Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA.

Ther Drug Monit. 2019 Aug;41(4):528-532. doi: 10.1097/FTD.0000000000000656.

PMID:
31259882
2.

Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the 1st month following renal transplantation.

Sallustio BC, Noll BD, Coller JK, Tuke J, Russ G, Somogyi AA.

Br J Clin Pharmacol. 2019 May;85(5):1015-1020. doi: 10.1111/bcp.13880. Epub 2019 Mar 6.

PMID:
30690767
3.

Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation.

Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA.

Pharmacogenet Genomics. 2019 Jan;29(1):9-17. doi: 10.1097/FPC.0000000000000360.

PMID:
30489455
4.

Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients.

Md Dom ZI, Coller JK, Carroll RP, Tuke J, McWhinney BC, Somogyi AA, Sallustio BC.

Br J Clin Pharmacol. 2018 Oct;84(10):2433-2442. doi: 10.1111/bcp.13704. Epub 2018 Aug 7.

5.

Enantioselectivity in the tissue distribution of perhexiline contributes to different effects on hepatic histology and peripheral neural function in rats.

Licari G, Milne RW, Somogyi AA, Sallustio BC.

Pharmacol Res Perspect. 2018 Jun;6(3):e00406. doi: 10.1002/prp2.406. Epub 2018 May 22.

6.

CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.

Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA.

Basic Clin Pharmacol Toxicol. 2018 Sep;123(3):320-326. doi: 10.1111/bcpt.13016. Epub 2018 May 7.

7.

Stereoselective handling of perhexiline: implications regarding accumulation within the human myocardium.

Chong CR, Drury NE, Licari G, Frenneaux MP, Horowitz JD, Pagano D, Sallustio BC.

Eur J Clin Pharmacol. 2015 Dec;71(12):1485-91. doi: 10.1007/s00228-015-1934-8. Epub 2015 Sep 16.

PMID:
26376650
8.
9.

Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague-Dawley and Dark Agouti rats.

Licari G, Somogyi AA, Milne RW, Sallustio BC.

Xenobiotica. 2015 Jan;45(1):3-9. doi: 10.3109/00498254.2014.942721. Epub 2014 Jul 22.

PMID:
25050791
10.

Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies.

Md Dom ZI, Noll BD, Coller JK, Somogyi AA, Russ GR, Hesselink DA, van Gelder T, Sallustio BC.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jan 15;945-946:171-7. doi: 10.1016/j.jchromb.2013.11.056. Epub 2013 Dec 4.

PMID:
24342510
11.

Perhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: an open-labeled clinical trial.

Kitoh H, Achiwa M, Kaneko H, Mishima K, Matsushita M, Kadono I, Horowitz JD, Sallustio BC, Ohno K, Ishiguro N.

Orphanet J Rare Dis. 2013 Oct 16;8:163. doi: 10.1186/1750-1172-8-163.

12.

Relationship between plasma, atrial and ventricular perhexiline concentrations in humans: insights into factors affecting myocardial uptake.

Drury NE, Licari G, Chong CR, Howell NJ, Frenneaux MP, Horowitz JD, Pagano D, Sallustio BC.

Br J Clin Pharmacol. 2014 May;77(5):789-95. doi: 10.1111/bcp.12254.

13.

Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies.

Noll BD, Coller JK, Somogyi AA, Morris RG, Russ GR, Hesselink DA, Van Gelder T, Sallustio BC.

Ther Drug Monit. 2013 Oct;35(5):617-23. doi: 10.1097/FTD.0b013e31828e8162.

PMID:
23921430
14.

Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies--a method suitable for small (<1 mg) samples.

Noll BD, Coller JK, Somogyi AA, Morris RG, Russ GR, Hesselink DA, van Gelder T, Sallustio BC.

Ther Drug Monit. 2011 Dec;33(6):688-93. doi: 10.1097/FTD.0b013e318236315d.

PMID:
22105584
15.

Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state pharmacokinetics of perhexiline.

Ling LH, Chik W, Averbuj P, Pati PK, Sverdlov AL, Ngo DT, Morris RG, Sallustio BC, Horowitz JD.

Ther Drug Monit. 2011 Apr;33(2):251-6. doi: 10.1097/FTD.0b013e31820dd8e9.

PMID:
21383654
16.

LC-MS/MS for immunosuppressant therapeutic drug monitoring.

Sallustio BC.

Bioanalysis. 2010 Jun;2(6):1141-53. doi: 10.4155/bio.10.58. Review.

PMID:
21083213
17.

Comparison of blood sirolimus, tacrolimus and everolimus concentrations measured by LC-MS/MS, HPLC-UV and immunoassay methods.

Sallustio BC, Noll BD, Morris RG.

Clin Biochem. 2011 Feb;44(2-3):231-6. doi: 10.1016/j.clinbiochem.2010.10.005. Epub 2010 Oct 21.

PMID:
20970416
18.

Glucuronidation of mycophenolic acid by Wistar and Mrp2-deficient TR- rat liver microsomes.

Westley IS, Morris RG, Evans AM, Sallustio BC.

Drug Metab Dispos. 2008 Jan;36(1):46-50. Epub 2007 Oct 1.

PMID:
17908922
19.

Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing human UDP-glucuronosyltransferases: role of acyl glucuronide metabolites and glycation pathways.

Southwood HT, DeGraaf YC, Mackenzie PI, Miners JO, Burcham PC, Sallustio BC.

Chem Res Toxicol. 2007 Oct;20(10):1520-7. Epub 2007 Sep 20.

PMID:
17880178
20.

Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline.

Davies BJ, Herbert MK, Coller JK, Somogyi AA, Milne RW, Sallustio BC.

Br J Clin Pharmacol. 2008 Mar;65(3):347-54. Epub 2007 Sep 13.

21.

Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.

Inglis SC, Herbert MK, Davies BJ, Coller JK, James HM, Horowitz JD, Morris RG, Milne RW, Somogyi AA, Sallustio BC.

Pharmacogenet Genomics. 2007 May;17(5):305-12.

PMID:
17429312
22.

CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes.

Davies BJ, Coller JK, Somogyi AA, Milne RW, Sallustio BC.

Drug Metab Dispos. 2007 Jan;35(1):128-38. Epub 2006 Oct 18.

PMID:
17050648
23.

Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography.

Davies BJ, Herbert MK, Coller JK, Somogyi AA, Milne RW, Sallustio BC.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Nov 7;843(2):302-9. Epub 2006 Jul 11.

PMID:
16837252
24.
25.
26.

Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography.

Davies BJ, Herbert MK, Culbert JA, Pyke SM, Coller JK, Somogyi AA, Milne RW, Sallustio BC.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 17;832(1):114-20. Epub 2006 Jan 24.

PMID:
16434242
27.

Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine.

Westley IS, Brogan LR, Morris RG, Evans AM, Sallustio BC.

Drug Metab Dispos. 2006 Feb;34(2):261-6. Epub 2005 Nov 4.

PMID:
16272406
28.
29.
30.

A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis.

James HM, Coller JK, Gillis D, Bahnisch J, Sallustio BC, Somogyi AA.

Int J Clin Pharmacol Ther. 2004 Dec;42(12):719-23.

PMID:
15624288
31.

Determination of perhexiline and hydroxyperhexiline in plasma by liquid chromatography-mass spectrometry.

Beck O, Stephanson N, Morris RG, Sallustio BC, Hjemdahl P.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jun 5;805(1):87-91.

PMID:
15113543
32.

Optimisation of the comet genotoxicity assay in freshly isolated murine hepatocytes: detection of strong in vitro DNA damaging properties for styrene.

Fontaine FR, DeGraaf YC, Ghaoui R, Sallustio BC, Edwards J, Burcham PC.

Toxicol In Vitro. 2004 Jun;18(3):343-50.

PMID:
15046782
33.

Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.

Davies BJ, Coller JK, James HM, Gillis D, Somogyi AA, Horowitz JD, Morris RG, Sallustio BC.

Br J Clin Pharmacol. 2004 Apr;57(4):456-63.

34.
35.

UDP-glucuronosyltransferase-dependent bioactivation of clofibric acid to a DNA-damaging intermediate in mouse hepatocytes.

Ghaoui R, Sallustio BC, Burcham PC, Fontaine FR.

Chem Biol Interact. 2003 May 6;145(2):201-11.

PMID:
12686496
36.
37.

In vivo perturbation of rat hepatocyte canalicular membrane function by diclofenac.

Sallustio BC, Holbrook FL.

Drug Metab Dispos. 2001 Dec;29(12):1535-8.

PMID:
11717171
38.

Hepatic disposition of electrophilic acyl glucuronide conjugates.

Sallustio BC, Sabordo L, Evans AM, Nation RL.

Curr Drug Metab. 2000 Sep;1(2):163-80. Review.

PMID:
11465081
39.
40.

In vitro covalent binding of nafenopin-CoA to human liver proteins.

Sallustio BC, Nunthasomboon S, Drogemuller CJ, Knights KM.

Toxicol Appl Pharmacol. 2000 Mar 1;163(2):176-82.

PMID:
10698675
41.
42.

Some international approaches to aminoglycoside monitoring in the extended dosing interval era.

Morris RG, Sallustio BC, Vinks AA, LeGatt DF, Verjee ZH, El Desoky E.

Ther Drug Monit. 1999 Aug;21(4):379-88. Review.

PMID:
10442690
43.
44.

Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service.

Morris RG, Black AB, Harris AL, Batty AB, Sallustio BC.

Br J Clin Pharmacol. 1998 Dec;46(6):547-51.

45.

Short-term myocardial uptake of d- and l-sotalol in humans: relation to hemodynamic and electrophysiologic effects.

Ritchie RH, Sallustio BC, Hii JT, Horowitz JD.

J Cardiovasc Pharmacol. 1998 Jun;31(6):876-84.

PMID:
9641472
46.
48.

Effects of gemfibrozil and clofibric acid on the uptake of taurocholate by isolated rat hepatocytes.

Sabordo L, Sallustio BC.

Biochem Pharmacol. 1997 Jul 1;54(1):215-8.

PMID:
9296370
49.

Reducing the cost of cyclosporin assays: modification of the EMIT 2000 method.

Sallustio BC, Morris RG, Saccoia NC, Mangas S, Kassapidis C.

Ther Drug Monit. 1997 Apr;19(2):208-11.

PMID:
9108652
50.

Interaction of human serum albumin with the electrophilic metabolite 1-O-gemfibrozil-beta-D-glucuronide.

Sallustio BC, Fairchild BA, Pannall PR.

Drug Metab Dispos. 1997 Jan;25(1):55-60.

PMID:
9010630

Supplemental Content

Loading ...
Support Center